patients. 1 Because of these initial improved outcomes there has been additional prospective reported trials demonstrating the effectiveness of DEBDOX with variable adverse event rates (Table 1) . [1] [2] [3] [4] [5] However, optimal safety and efficacy still remains unanswered through the use of various bead sizes, various doxorubicin doses delivered, and various degrees of stasis, following bead infusion with the mixed results of additional embolic agents utilized after initial DEBDOX use. Continued debate continues in regards to conventional TACE in regards to the additional use of embolic particles and the optimal dosing of chemotherapeutic agent. [6] [7] [8] [9] Recent prospective single arm and randomized phase II trials continue to demonstrate this variable use with all type of bead sizes and bead combinations being utilized with concomitant variable adverse event rates and fairly comparable response rates (Table 1) . [1] [2] [3] [4] [5] Thus, the aim of this study was to assess the optimal safety 
PATIENTS AND METHODS

Patients
Treatment with DEBDOX and outcomes
Diagnostic angiography was performed by an interventional radiologist and consisted of selective celiac and superior mesenteric arteriogram to evaluate the hepatic arterial anatomy. For tumors near the periphery of the liver, evaluation of potential extrahepatic supply to the tumors such as the inferior phrenic, gastroepiploic and internal mammary arteries was performed. Once the degree of hepatic tumor perfusion was evaluated, the next step was to limit any type of extrahepatic perfusion of the chemotherapeutic treatment.
The most common branches that will lead to extrahepatic disposition of treatment are the right gastric and the gastroduodenal arteries, which are either controlled prior to infusion using coil embolization, or distal catheter placement.
In addition, particular attention is paid to identification of the cystic artery to ensure that the catheter tip is past this point. This avoids extrahepatic infusion of embolic material into the gallbladder and maximizes therapy control.
The bead size used for each patient was up to the treating interventional radiologist, since at the time of this study no optimal bead size had been described. Similarly there are also, similar elution characteristics in all bead sizes, and thus the type of bead was not standardized. 
Statistical analysis
RESULTS
A total of 206 patients were included in this review with a majority of patients being treated either with a small bead combination (100-300 μ beads alone) or a medium bead combination (one vial 300-500 μ and one vial 500-700 μ)
followed by a mixed bead combination (one vial of 100-300 μ and one vial of 300-500 μ) with the smallest number being patients treated with large beads alone (500-700 μ only). All four groups above were similar in age as well as male-tofemale distribution as demonstrated in Table 2 Of the 206 patients, a total of 343 DEBDOX treatments were performed. Table 3 The types and severity of complications were fairly similar across all four groups (Table 4) medium or large bead size (Table 5 ).
In a review of other predictive factors for adverse event rates, there was a statistically significant increase in overall adverse event rates in patients who underwent the angiographic endpoint of either a complete stasis or a near stasis with nearly double adverse event rates in patients who had partial stasis (Table 6) . Similarly there was also a statistically significant increase in adverse advent rates in patients who were treated in a sub-segmental DEBDOX infusion in relation to patients who received only lobar or segmental infusion, however, there were no significant differences in adverse event rates related to the doxorubicin dose delivered with similar adverse event rates in patients who received less than equal to 75 mg (7% adverse event rate), 76-150 mg (5% adverse event rate) or 150 mg (11% adverse event rates).
Similarly, regardless if a patient was undergoing their first bead treatment or their, fourth bead treatment, there was also none statistically significant difference in overall adverse event rates, regardless of the number of bead treatments that the patient was undergoing.
In a review of 6 month and 12 months response rates there were similar response rates in all four groups (Table 7) , with small bead demonstrating 6 months of 73% and 12 month of 61%, Mixed was 88% and 50%, Medium was 60% and 57%, and Large was 57% and 46% respectively. After a median follow up of 12 months, similar overall survival was seen in all groups with small bead median of 16 months, mixed 13 months, medium 14 months, and large 11 months (P=0.2).
DISCUSSION
DEBDOX has been proven in multiple studies to demonstrate enhanced anti-tumor effects with similar or increased survival and decrease in overall side effects related to other hepatic arterial therapies. Response rates in all series have ranged from as low as 50% at 6 months, to as high as 70% at 6 months based on various reports. Varela et al 10 reported
response rates of 60-70% and similarly reported only minor overall adverse event rate of 18%, even with the use of a single vial of 500-700 μ beads but did report 2 patients with liver abscess (7.4%) and 1 death (3.7%). The degree of stasis and degree of doxorubicin dose delivered for this specific patient is not revealed in this manuscript and thus the true source for this adverse event rate is not able to be delineated.
A similar smaller Phase II study by Poon et al 11 also used the same bead size and did demonstrate an a small adverse event rate of 11% and did not report any liver abscess or death, thus demonstrating the potential safety of beads up to 500-700 μ in size.
However, in contrast, the recent randomized phase II Precision V Trial, which utilized a combination bead size of 300-500 μ followed by 500-700 μ beads showed a dramatic In an evaluation of a smaller bead size combination by Malagari et al 13 who utilized a 100-300 μ and then 300-500 μ bead size, adverse event rates were dramatically less with an overall of 22%. The explanation for the use of 100-300 μ and 300-500 μ are specifically explained in this trial and are related to lesion size (<6 cm or ≥6 cm or the presence or absence of arteriovenous shunts). Given that this was an overall survival comparison of DEBDOX to bland embolization, the evaluation of the bead size, degree of stasis, and degree of doxorubicin and drug delivered, was not a primary end point and thus was not reported in this manuscript. They did, however, report a liver abscess rate of 4.8% and a liver failure rate, also of 4.8%, similar to the previously reported trials.
All of the previous studies present an overall adverse event rates, but do not answer what is the optimal bead size, optimal doxorubicin dose and angiographic techniques. Herein the results of this prospective multi institutional registry does demonstrate a statistically significant increase in overall adverse event rates as well as severe adverse event rates, being death in patients who are receiving a larger bead combination of either 300-500 μ, 500-700 μ, or 500-700 μ alone. The predominant predictors of this adverse event rate do appear to be generated because of a higher incidence of complete stasis as well as a preponderance for a segmental or sub-segmental bead infusion. Lastly, this group of larger bead size was also more commonly being treated with additional embolic agents following DEBDOX treatment, thus potentiating the overall anoxic event and leading to a greater incidence of complications relative to hepatic ischemia. In contrast, even though there was a greater incidence of either complete or near stasis we do not see an enhanced response rate at either 6 or 12 months in patients treated with a larger bead size.
Thus, calling into the question as to whether efficacy is improved by either relative hypoxia and repeated at doxorubicin drug delivery versus complete anoxia at the time of initial chemoembolization therapy. [14] [15] [16] This data does not allow us to answer that question but does demonstrate significant better tolerance and improvement in overall survival in patients who were able to undergo repeated DEBDOX based treatment. This improvement in overall survival appears to be related to a greater tolerance of the patient and the subsequent tolerance of the diseased liver to then undergo repeated bead treatments because of a reduction in overall adverse event rates. Given the complexity of treating HCC is a bi-modal type of disease, that being treatment of both the cancer as well as the underlying hepatic parenchyma, it is reasonable to assume that a greater tolerance of treatment that is able to be able to retreat at set intervals would portend to an improvement in overall outcomes because of a reduction in toxicity. This logic is well established in the medical oncology literature in the fact that patients who have significant toxicity and are reliant on significant dose reduction of systemic chemotherapy or dose delays of systemic chemotherapy do not achieve the similar benefits of patients who are able to be treated at full dose and on schedule. It is thus acceptable to make that correlation with the use of DEBDOX based treatment in that patients who are unable to undergo repeated treatments at appropriate intervals with reduced toxicity will thus have an improved overall outcome versus patients who are only able to be undertreated with significant toxicity. The limitations of this study are also, potentially, the benefits in that this evaluation was not formed on an established prospective protocol. However, the data present is real clinical practice in patients who are initiating DEBDOX based treatment in their interventional oncology practices. We believe that this, obviously, demonstrates a more clinically relevant and more clinically practical use of this device and believe that this type of prospective evaluation and review will allow additional new users and established DEBDOX users at the present to consider technical changes. However, we acknowledge that since this is not a randomized trial of all four bead sizes there is inherent bias that can be conveyed.
We believe the similar groups based on disease presentation overcome some of this bias, but a randomized trial would be the optimal study to confirm these observational results.
Thus, in conclusion, based on this review of optimal bead size, optimal doxorubicin dosing, as well as angiographic technique, the smallest bead size being 100-300 μ offers the ability of repeat retreatment at appropriate intervals. This then allows for a larger cumulative dose delivery, less degree of complete stasis, fewer adverse event rates, and reduction in the severity of adverse event rates.
